The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | The biggest evidence gaps in the treatment of hematologic malignancies in pregnancy
Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, outlines the current evidence gaps when it comes to the treatment of hematologic malignancies during pregnancy, highlighting the need for more information on the effects of newer therapies and the importance of longer follow-up to determine the potential impact of antenatal chemotherapy on fertility and secondary malignancies in the child. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the most important is the introduction of the newer therapies. Hematology is a field which is developing very, very quickly. So we need to see whether those new therapies can be incorporated also during the pregnancy. But therefore, we need some more information on placental transfer of those therapies. What effect do they have? And the second gap, I think, is we now have follow-up in children until 18 to 20 years...
I think the most important is the introduction of the newer therapies. Hematology is a field which is developing very, very quickly. So we need to see whether those new therapies can be incorporated also during the pregnancy. But therefore, we need some more information on placental transfer of those therapies. What effect do they have? And the second gap, I think, is we now have follow-up in children until 18 to 20 years. But what we don’t know for sure is whether getting chemotherapy during the pregnancy for the baby, whether this has an effect on fertility later on during life or even on secondary malignancies later in life. We don’t have any arguments that they are increased at this moment, but we still need some longer follow-up.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
